As of 2025, BeOne Medicines has disclosed 3 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 3 intensity-based targets, signaling the company's commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into BeOne Medicines's climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Intensity-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) per Kilogram (kg) of Unspecified Product Produced/Manufactured | -25%a, b | 2026 |
Intensity-based Target | Scope 3 - Purchased Goods and Services (Cat. 1), Scope 3 - Capital Goods (Cat. 2), Scope 3 - Waste Generated in Operations (Cat. 5) | Metric Tonnes of CO2 equivalent (mtCO2e) per Kilogram (kg) of Unspecified Product Produced/Manufactured | -10%a | 2030 |
Intensity-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) per Kilogram (kg) of Unspecified Product Produced/Manufactured | -50%a | 2030 |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
As of 2025, BeOne Medicines has set greenhouse gas (GHG) emissions reduction targets that cover both its operational emissions (Scope 1 and 2) and value chain emissions (Scope 3), offering a comprehensive view of its total carbon footprint.ab
As of 2025, BeOne Medicines has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.ab
BeOne Medicines's most ambitious operational target is to reduce these emissions by 50% by 2030, compared to a baseline of 1.96 Metric Tonnes of CO2 equivalent (mtCO2e) per Kilogram (kg) of Unspecified Product Produced/Manufactured in 2024.ab
As of 2025, BeOne Medicines is ahead of schedule on its operational emissions reduction target, having achieved 40.82% of the planned reduction.ab